Dietary Treatments for Cognitive Impairment in Older Adults
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02521818 |
Recruitment Status :
Completed
First Posted : August 13, 2015
Last Update Posted : September 6, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Mild Cognitive Impairment Probable Alzheimer's Disease | Other: Modified Atkins Diet Other: NIA Diet for Seniors | Not Applicable |
It is well established that Alzheimer's disease (AD) is associated with insulin resistance and, hence, abnormal glucose metabolism. In fact, abnormalities in the brain's uptake of glucose can be observed on PET imaging in advance of clinical symptoms. In patients with established dementia due to AD, the severity of cognitive impairment is strongly correlated with the decrease in glucose uptake. Ketone bodies, the products of fat metabolism, can serve as a "backup" fuel when glucose is unavailable. Ketone body metabolism appears to bypass the metabolic processes that are abnormal in AD and may provide better nourishment for neurons. As a result, ketone body metabolism may slow cognitive decline or even improve cognition in patients with AD.
Participants will be 60 people, age 60 or older, with MCI or mild probable AD and without significant cardiovascular disease. They will be required to obtain the consent of their primary care physicians for their participation. Each patient will have a study partner who is cognitively healthy, lives with the participant, and can help him/her adhere to the diet. A research dietitian will teach participants and partners the new diet and monitor participants' adherence with food logs, in-person assessments, and urine ketone testing. After an initial baseline visit, participants will complete four in-person assessments during which adherence to the diet will be assessed and neurocognitive tests will be administered. It is hypothesized that the MAD will be feasible and well tolerated by seniors with MCI and AD. It is further hypothesized that adherence to the MAD will be associated with a greater increase (or less decline) in cognitive test scores than the placebo diet, particularly for those participants who do not carry an ApoE ε4 allele.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 38 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Feasibility and Efficacy of Dietary Interventions for Cognitive Impairment in Older Adults |
Actual Study Start Date : | August 2015 |
Actual Primary Completion Date : | July 1, 2019 |
Actual Study Completion Date : | July 1, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Modified Atkins Diet
modified Atkins diet; fewer than 20 mg. carbohydrates per day, supplemented by extra dietary fats
|
Other: Modified Atkins Diet
Other Name: ketogenic diet |
Active Comparator: NIA Diet for Seniors
Diet recommended by NIA for seniors
|
Other: NIA Diet for Seniors |
- Feasibility for MAD Group [ Time Frame: 12 weeks ]Achieving moderate ketosis (>=40 mg.dl) at 3 consecutive follow-up visits
- Feasibility for Control Group [ Time Frame: 12 weeks ]Achieving a Healthy Eating Index (>=85) at 3 consecutive follow-up visits
- Efficacy for Cognition [ Time Frame: 12 weeks ]Composite Memory Score (mean z-score on delayed recall of HVLT-R and BVMT-R)
- Efficacy for Function [ Time Frame: 12 weeks ]Change in MDS-HC Instrumental Activities of Daily Living Score

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosis of mild cognitive impairment or Alzheimer's disease
- availability of cohabitating study partner without cognitive impairment
- consent of primary care physician
Exclusion Criteria:
- history of stroke
- history of coronary artery disease
- history of pancreatitis
- untreated hypothyroidism or B12 deficiency
- history of renal disease or recurrent kidney stones
- history of liver disease
- insulin-dependent diabetes
- body mass index <18.5
- multiple food allergies
- follow strict diet (e.g., vegetarian, gluten-free)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02521818
United States, Maryland | |
Johns Hopkins Hospital | |
Baltimore, Maryland, United States, 21205 |
Principal Investigator: | Jason Brandt, Ph.D. | Johns Hopkins University |
Responsible Party: | Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT02521818 |
Other Study ID Numbers: |
IRB00066092 |
First Posted: | August 13, 2015 Key Record Dates |
Last Update Posted: | September 6, 2019 |
Last Verified: | September 2019 |
cognition dementia neuropsychological |
elderly nutrition diet |
Alzheimer Disease Cognitive Dysfunction Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Cognition Disorders |